Mepolizumab 300 mg ( DrugBank: Mepolizumab )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
98	好酸球性消化管疾患	1

98. 好酸球性消化管疾患

---

臨床試験数 : 171 /  薬物数 : 184 - (DrugBank : 47) / 標的遺伝子数 : 42 - 標的パスウェイ数 : 141

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03656380 (ClinicalTrials.gov)	March 20, 2019	30/8/2018	Mepo for EoE Study	A Multi-center, Randomized, Double Blind, Parallel-arm, Placebo Controlled Trial of Mepolizumab for Treatment of Adults and Adolescents With Active Eosinophilic Esophagitis and Dysphagia-predominant Symptoms	EoE;Eosinophilic Esophagitis	Drug: Mepolizumab 300 mg;Drug: Mepolizumab 100 mg;Other: Placebo	University of North Carolina, Chapel Hill	GlaxoSmithKline;University of Utah;Northwestern University;MNGI Digestive Health, P.A.	Recruiting	16 Years	75 Years	All	72	Phase 2	United States